english.prescrire.org > Spotlight > Archives : 2020 > Denosumab (Prolia°) and steroid-induced osteoporosis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

In the April issue of Prescrire International: Denosumab (Prolia°) and steroid-induced osteoporosis

FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation?
Full text available for free download.

Prescrire's rating

  •  NOT ACCEPTABLE  Denosumab has not been shown to prevent clinical fractures, but it has many adverse effects that can be severe or even fatal, including deep infections, hypocalcaemia, osteonecrosis and multiple vertebral fractures after discontinuation.

 ©Prescrire 1 April 2020

Full text available for free download.

"Denosumab (Prolia°) and steroid-induced osteoporosis" Prescrire Int 2020; 29 (214): 95. (Pdf, free).

Share Share on Facebook Share on Twitter
Partager sur Facebook Partager sur Twitter

Download the full review
Pdf, free

Prescrire's rating:
Prescrire's rating
See also:

EMA turns a blind eye
to denosumab's lack of
proven clinical efficacy
Prescrire Int 2020:
29 (214): 96.
Pdf, free

New drugs: the right
to know
Prescrire Int 2020:
29 (214): 87.
Pdf, free